4//SEC Filing
Landau Jeffrey B 4
Accession 0001567619-23-001929
CIK 0001501989other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 4:49 PM ET
Size
11.4 KB
Accession
0001567619-23-001929
Insider Transaction Report
Form 4
Landau Jeffrey B
Chief Business Officer
Transactions
- Award
Common Stock
2023-02-02+40,000→ 70,725 total - Award
Performance Stock Units (PSUs)
2023-02-02+75,000→ 75,000 total→ Common Stock (75,000 underlying) - Award
Stock Option (Right to Buy)
2023-02-02+100,000→ 100,000 totalExercise: $2.59Exp: 2033-02-01→ Common Stock (100,000 underlying)
Holdings
- 3,180(indirect: By IRA)
Common Stock
- 4,500(indirect: By IRA)
Common Stock
Footnotes (4)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 56,274 RSUs.
- [F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
- [F4]Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001918615
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 4:49 PM ET
- Size
- 11.4 KB